VPOP2: Postoperative Vomiting in Children: Comparison Tri - Versus bi -Prophylaxis

Sponsor
Assistance Publique - Hôpitaux de Paris (Other)
Overall Status
Completed
CT.gov ID
NCT01739985
Collaborator
(none)
322
1
2
41
7.9

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the benefit of addition of droperidol to prophylaxis with ondansetron and dexamethasone in children with high risk of postoperative vomiting (POV). In adults some authors showed that the effectiveness of prophylaxis is correlated to the number of molecules or specific procedures used.

Condition or Disease Intervention/Treatment Phase
  • Drug: Dexamethasone + ondansetron + Placebo
  • Drug: Dexamethasone + ondansetron + Droperidol
N/A

Detailed Description

The overall incidence of postoperative vomiting between 25 and 30% for the pediatric population, but it can reach a much higher incidence associated with certain types of surgery, about 80% in some studies like strabismus surgery for example. The identification of patients at high risk of POV is possible through the use of risk score. It is currently only one pediatric validated risk score, but the investigators conducted a multicenter study on this subject, whose results are being analyzed. This should allow us to identify children at high risk of POV. In this targeted population, the prophylaxis should allow a significant reduction in the incidence of POV. In children only one study tried to evaluate the association of ondansetron, dexamethasone and droperidol to prevent postoperative vomiting. However, different doses of the different molecules were combined, the extremely complicated design of this study and important methodological bias do not provide evidence about the superiority of the combination of three anti-emetics compared with two anti-emetics. Our present randomized, double-blind study is designed to compare the effectiveness of Droperidol in combination with a conventional bi-prophylaxis (dexamethasone/ondansetron) to the conventional bi-prophylaxis alone to decrease the occurrence of postoperative vomiting in children at high risk. The combination ondansetron and dexamethasone is frequently assessed as an association to prevent postoperative vomiting also in the adult population and in the pediatric population.

Study Design

Study Type:
Interventional
Actual Enrollment :
322 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Prevention
Official Title:
Postoperative Vomiting in Children: Evaluation of the Addition of Droperidol to Conventional Bi-prophylaxis
Study Start Date :
Dec 1, 2010
Actual Primary Completion Date :
Jul 1, 2013
Actual Study Completion Date :
May 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Dexamethasone + ondansetron + Placebo

dexamethasone + ondansetron + Placebo

Drug: Dexamethasone + ondansetron + Placebo
Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery

Experimental: Dexamethasone + ondansetron + Droperidol

dexamethasone + ondansetron + Droperidol

Drug: Dexamethasone + ondansetron + Droperidol
Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1

Outcome Measures

Primary Outcome Measures

  1. Postoperative vomiting [24 hours]

Secondary Outcome Measures

  1. Safety and Tolerability [24 hours]

    Number of Participants with Adverse Events as a Measure of Safety and Tolerability

Eligibility Criteria

Criteria

Ages Eligible for Study:
3 Years to 17 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children scheduled for surgery and with high risk of postoperative vomiting, i.e. with VPOP score up to 4

  • Between 3 to 18 years

  • Informed consent signed or the owner (s) of parental

  • Children receiving a social security system

Exclusion Criteria:
  • Ambulatory surgery

  • Preoperative corticosteroids

  • Postoperative sedation

  • Allergy known to droperidol, ondansetron or dexamethasone

  • Known hypokaliemia

  • Known hypomagnesemia

  • Bradycardia (<55 bpm)

  • Congenital long QT syndrome

  • Treatment that induce prolonged QT

  • Pheochromocytoma

  • Severe depressive syndrome

Contacts and Locations

Locations

Site City State Country Postal Code
1 Necker Hospital Paris France 75015

Sponsors and Collaborators

  • Assistance Publique - Hôpitaux de Paris

Investigators

  • Study Chair: Gilles ORLIAGUET, MD, PhD, Necker Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier:
NCT01739985
Other Study ID Numbers:
  • P081228
  • 2009-017293-20
First Posted:
Dec 4, 2012
Last Update Posted:
Jul 28, 2014
Last Verified:
Aug 1, 2013

Study Results

No Results Posted as of Jul 28, 2014